Observational studyAnnals of surgical oncology2026
Potential Impact of Sentinel Lymph Node Biopsy Omission on Adjuvant Treatment Decisions in Low-Risk Breast Cancer: A Regional Multicenter 775 Patient Review of Current Practice in the United Kingdom.
Observational study in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized controlled trials support the omission of sentinel lymph node biopsy (SLNB) in low-risk breast cancer. This study investigates the rate of nodal involvement and associated clinical factors and if the result of SLNB influences adjuvant treatment decisions. PATIENTS AND
methodsAll patients diagnosed with ER
resultsOverall, 755/775 (97.4%) patients underwent axillary surgery and 82/755 (10.9%) were node positive. Clinical and invasive pathological tumor size was significantly associated with nodal involvement [cT1a 0/19 (0.0%), cT1b 10/191 (5.2%), cT1c 70/545 (12.8%), P = 0.019; pT1a 0/41 (0.0%), pT1b 10/205 (4.9%), pT1c 52/241 (12.3%), pT2 19/82 (23.2%), P < 0.001]. Nodal involvement was significantly associated with the use of partial breast radiotherapy [node negative 262/625 (41.9%) versus node positive 0/81 (0.0%), P < 0.001]. Node-positive patients were significantly more likely to receive aromatase inhibitor therapy versus tamoxifen [75/81 (92.6%) versus 5/81 (6.2%), P < 0.001].
conclusionsThe rate of nodal involvement is low, supporting the omission of SLNB. The result of SLNB influences adjuvant treatment decisions in this low-risk cohort. Although there is enthusiasm to omit SLNB, consideration must be given to this, and omission should be performed in the context of multi-disciplinary discussions.
Indexed as
Identifiers
42406215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.